New drug target for an aggressive form of Prostate Cancer – ICR

Alexandros Papachristodoulou shared a post by Institute of Cancer Research on X, adding:

“Beautiful work by Adam Sharp et al., highlighting the need for rational combinatorial strategies to effectively treat mCRPC. Love to see biomarker-driven prostate cancer research!”

Quoting Institute of Cancer Research’s post:

“NEWS: Scientists have discovered a new drug target for an aggressive form of Prostate Cancer.

Published in Journal of Clinical Investigation, they found a protein associated with worse outcomes, which could be screened for to develop personalised treatment plans.”

BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity

Authors: Daniel Westaby, Juan M. Jiménez-Vacas, Ines Figueiredo, Jan Rekowski, Claire Pettinger, Bora Gurel, Arian Lundberg, Denisa Bogdan, Lorenzo Buroni, Antje Neeb, Ana Padilha, Joe Taylor, Wanting Zeng, Souvik Das, Emily Hobern, Ruth Riisnaes, Mateus Crespo, Susana Miranda, Ana Ferreira, Brian P. Hanratty, Daniel Nava Rodrigues, Claudia Bertan, George Seed, Maria de Los Dolores Fenor de La Maza, Christina Guo, Juliet Carmichael, Rafael Grochot, Khobe Chandran, Anastasia Stavridi, Andreas Varkaris, Nataly Stylianou, Brett G. Hollier, Nina Tunariu, Steven P. Balk, Suzanne Carreira, Wei Yuan, Peter S. Nelson, Eva Corey, Michael Haffner, Johann de Bono, and Adam Sharp

Source: Alexandros Papachristodoulou/X and ICR/X

Alexandros Papachristodoulou is a Postdoctoral Researcher at Columbia University Irving Medical Center. He has received several awards, including the Swiss National Science Foundation Fellowship (2018), Prostate Cancer Foundation Young Investigator Award (2021), HICCC Postdoctoral Pilot and Early Career Development Pilot Awards (2022), and the NCI K99/R00 Pathway to Independence Award (2023). His research focuses on cancer biology and related methodologies.

Adam Sharp is the Leader of the Translational Therapeutics Group and an Honorary Consultant Medical Oncologist in the Prostate Cancer Targeted Therapies Group and Drug Development Unit at the ICR and The Royal Marsden NHS Foundation Trust. His work focuses on developing novel therapeutic strategies for advanced prostate cancer, translating research from bench to bedside. He has published and presented extensively in this field